Opinions

A no-deal scenario the likely outcome. That’s the news of the day. The ever eternal optimists will be hoping for good news before the markets close…

The FDA is due to review BioNTech/Pfizer Inc.’s vaccine later today. Approval is a must to support riskier assets and give some hope to the worst affected.

The British PM and EU President agree to a Sunday deadline. Make or break talks will now continue and the Pound could come under fire…

It’s all eyes on Brussels, with British PM Johnson looking to salvage a Brexit deal. A failure to agree on a way forward would sink the Pound.

The Pound slides back to $1.32 levels off the back of gloomy Brexit updates. Pound sensitivity will be on the rise as time now rapidly runs out.

With the UK set to begin vaccinations this week and the FDA to review the Pfizer Inc. vaccine, production and logistics news will be of particular interest.

Are we in for one more Brexit shock?

The UK becomes the first nation to approve a COVID-19 vaccine and with an efficacy rate of 95%, an end to the pandemic may be in sight.

Time is running out and yet both sides stand firm on the remaining hurdles. The markets and the Pound continue to reflect optimism, however.

Moderna Inc. submits its EUA to the FDA, with both Pfizer Inc. and Moderna Inc. also submitting requests to the EMA.

AstraZeneca last week announced plans to launch a new global trial. Without the AstraZeneca vaccine, however, many nations will be without…

There is some rotation from tech stocks into cyclical stocks.

As more details emerge from AstraZeneca’s clinical trials, the door may be ajar for another U.S pharma to make a move.

As Brexit talks get set to resume, Boris may be feeling hot under the collar. A message from Biden and a warning from the EU. Compromise or else…

Face to face talks are set to resume with Barnier coming out of self-isolation. The two sides at odds, however, with time running out.

AstraZeneca and the University of Oxford fail to impress the markets with phase 3 trial results. Logistics and production could favor their vaccine, however.

Pfizer Inc. and BioNTech submit a EUA. Moderna Inc. and AstraZeneca need to catch up…

Brexit talks hit pause as EU negotiators self-isolate. With the transition period ending in just over a month, is an extension around the corner?

Pfizer Inc. addresses safety concerns and virus efficacy amongst the elderly. Is it enough for the FDA to approve and for manufacturing to commence?

The proverbial can continues to get kicked down the road. Brexit talks continue and the EU Summit on Thursday may not be the end of it.